Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050063 · ClinicalTrials.gov registry record
Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 78
- Enrollment target
NCT00050063 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 78 participants.
The verdict
NCT00050063 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
Interventions
- BIOLOGICAL Therapeutic vaccinations from A5058s
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Est. Completion | 2004-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050063
The ClinicalTrials.gov registry entry for NCT00050063 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Therapeutic vaccinations from A5058s is the first listed.
NCT00050063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050063 about?
NCT00050063 is a clinical study titled "Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs". The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
What is the current status of trial NCT00050063?
This trial is currently completed. The enrollment target is 78 participants. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00050063?
The interventions under investigation include: Therapeutic vaccinations from A5058s (BIOLOGICAL).
Who is sponsoring clinical trial NCT00050063?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.